Six Principles, One Guardrail: The MHRA's Blueprint For Regulating Advanced Therapies

The keynote, "Regulatory principles shaping the future of advanced therapies," set up the panel that followed it directly. Rather than a broad vision statement, George walked through specific, live mechanisms the MHRA is already deploying, and closed with a single guardrail that applies to all of them.

Getting the whole system talking before the science arrives

George's opening point was structural rather than scientific: regulatory success depends on identifying cross-agency dependencies early, so every party involved in getting a product from discovery to patient, not just the regulator, is speaking to each other from the outset.

He pointed to two concrete mechanisms delivering this. The aligned pathway between the MHRA and NICE brings the regulator and the health technology assessment body together from the very start of development, so developers are asked the right questions once, by both bodies, rather than twice in sequence. The Innovative Licensing and Access Pathway (ILAP) goes further still, bringing the whole of NHS England, Scotland, Wales and Northern Ireland into the conversation from Phase 1 onwards, shaping pivotal study design so that market access and patient access happen as close together as possible.

His framing was explicit: this is a whole ecosystem, and nobody in it works in isolation. That means being patient-focused and lifecycle-based, not just at the point of approval, but through access, equity, long-term follow-up and real-world evidence, because, as he put it plainly, traditional clinical trial design clearly doesn't work for many rare diseases and advanced therapies.

Reclassifying mRNA cancer immunotherapies: medicines, not vaccines

The keynote's most concrete regulatory decision concerned individualised mRNA cancer immunotherapies, and it's a genuinely significant reclassification. Consultation has closed, final responses have been received, and the draft guidance is now in review on the UK government website.

The MHRA's proposed approach: regulate these products as medicines under the UK Human Medicines Act, not as vaccines. Where they meet the definition of a biological product, they'll be treated as ATMPs and subclassified as gene therapies. That reclassification matters practically because it opens up risk-proportionate, risk-based regulatory treatment, and crucially, it enables a single marketing authorisation even where each individual batch is tailored to a specific patient's characteristics, provided the underlying product design, manufacturing sites and manufacturing process remain consistent across those variable batches.

George was careful to frame this as flexibility with guardrails attached, not flexibility instead of them: predefined processes and controls stay in place precisely so that safe and effective clinical use is protected even as individualisation is enabled.

The world's first framework for microfactories

George's second major announcement concerned manufacturing itself: a draft framework for decentralised and modular manufacture, which he described as the world's first regulatory framework of its kind enacted via the Human Medicines Act.

The framework splits into two models. Point-of-care manufacture addresses products with very short half-lives that need to reach the patient almost immediately. Modular manufacture is the more structurally ambitious of the two: prefabricated, relocatable, self-contained microfactories operating on a hub-and-spoke model, where a central hub holds the marketing authorisation and controls quality management systems, while spokes enable genuinely decentralised production. George noted the MHRA is already seeing significant industry interest in this framework.

Letting evidence do more, without letting standards do less

A recurring thread through the keynote was support for reusing prior knowledge and accumulated evidence, particularly relevant for rare diseases where randomised controlled trials simply aren't statistically feasible given small patient numbers. Where scientifically justified, the MHRA will accept prior knowledge and real-world data as part of a submission, assessed in the round rather than dismissed for not fitting a traditional trial structure.

This extends into genuinely novel trial design. The MHRA runs live sandboxes and services including in-silico trials, and George revealed the regulator is about to publish guidance for what he described as the world's first series of fully hybrid clinical trials, incorporating digital twins and virtual humans to expand effective trial numbers and enable more innovative efficacy designs. Again, the underlying logic was consistent: traditional trial design simply isn't feasible for much of this field, so the regulatory tools need to change to match the science, not the other way round.

On AI specifically, George stated that the UK is the first major regulator globally to formalise AI and machine learning oversight within mandatory pre-inspection frameworks, covering everything from systems readiness to governance, moving the conversation from abstract principles to genuine inspection readiness.

He also acknowledged a subtler point that's easy to miss: evidence generation looks fundamentally different depending on context. Information-poor, replicate-sparse settings (true n-of-1 diseases), information-rich but still replicate-sparse settings (well-characterised rare diseases), and genuinely replicate-dense settings each demand a different regulatory approach, because treating them identically would be a category error. The MHRA's stated aim is to support innovators differently depending on which of these environments their evidence actually sits in.

He rounded off the practical detail with a nod to the British Pharmacopoeia's guidance on analytical and quality challenges, calling it a genuinely valuable resource, and to the MHRA's own extensive regulatory science research programme, which exists specifically to keep regulatory policy connected to an active evidence generation and translation pipeline, rather than regulating technology the agency doesn't yet fully understand.

The guardrail that ties it all together

For all the flexibility on offer, George was unambiguous about where the line sits. Flexibility should never be granted simply because an approach is novel or cheaper. It has to be justified by evidence, by genuine clinical benefit, and by the necessary features of the specific product or delivery model in question. Safety, quality and efficacy remain, in his words, the essential driving factor throughout.

He closed by naming the MHRA's six guiding principles directly: technology neutral, agile, risk proportionate, internationally convergent where possible and divergent where necessary, patient focused, and lifecycle based, with reuse of prior knowledge wherever it's scientifically justified.

His final line was the one worth remembering: flexibility must be evidence-led, controlled, internationally compatible wherever possible, and equitable, but safety, quality and efficacy must remain paramount across the whole lifecycle of a drug's development. Innovation gets enabled. Standards don't get lowered. Both at once, or not at all.

Why this matters beyond the room

What made this keynote a genuinely useful scene-setter, rather than a policy preamble, was the sheer density of live, named mechanisms behind it: an aligned pathway already running, a manufacturing framework already in draft, a reclassification decision already through consultation, and a hybrid trial guidance already coming. This wasn't a regulator describing intentions. It was a regulator showing its working.

That level of concrete regulatory detail is exactly the kind of session that sets the tone for a room, and it's a preview of what Advanced Therapies Europe brings to the stage every year.

Want the rest of the story? Register your interest for Advanced Therapies Europe 2027 and be first to hear when sessions and speakers go live.